It was approved on May 2021 by the FDA as a radioactive diagnostic tool, thanks to which it is possible to obtain accurate and early information on prostate cancer metastases, even in those patients with low prostate-specific antigen (PSA) levels [39,40]. Here, KLK3 is linked to prostate carcinoma.